Bristol Myers Squibb Co. stock rises Friday, still underperforms market
The stock's fall snapped a two-day winning streak.
Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1
The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Companies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costs
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Hosted on MSN1d
Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma
Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Drugmakers to raise US prices on over 250 medicines starting Jan. 1
The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...
Bristol-Myers Squibb's Long-term Dividend Outlook appears Promising
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...